Cellectar biosciences announces successful completion of phase 1 dose escalation study

Cellectar biosciences announces clr 131 achieves primary efficacy endpoints from its phase 2 clover-1 study in relapsed/refractory b-cell lymphomas and completion of the phase 1 relapsed/refractory multiple myeloma dose escalation study.cellectar biosciences inc - also announced successful completion of phase 1 dose escalation study.
CLRB Ratings Summary
CLRB Quant Ranking